

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

<b>Statement of Discontinuation of the study</b>	
<b>Name of Company:</b> GlaxoSmithKline	
<b>Study No:</b> 204810 (EudraCT# 2016-002733-30)	
<b>Product:</b> GSK3003891A	
<b>Title:</b> A Phase I/II, randomised, observer-blind, controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals' investigational RSV vaccine (GSK3003891A), in healthy pregnant women aged 18 to 40 years and infants born to vaccinated mothers	
<b>Phase:</b> II	
<b>Study Period:</b> NA	
<b>Centres</b> NA	
<b>Number of Subjects:</b> 0	
<b>Publications:</b> NA	
<b>Statement on discontinuation of the study:</b> Discontinued by GlaxoSmithKline during preparation of the trial. No patient entered the study; therefore, no results / data are available.	